Quest PharmaTech Inc.

Equities

QPT

CA74836M1068

Biotechnology & Medical Research

Market Closed - Toronto S.E. Other stock markets 10:28:43 2024-07-12 am EDT			5-day change	1st Jan Change
0.03 ^CAD	0.00%		0.00%	-45.45%

Jun. 28	Quest PharmaTech Inc. Reports Earnings Results for the First Quarter Ended April 30, 2024	CI
May. 30	Quest Pharmatech Inc. Announces the Appointment of Bradley J. Glass to the Board of Directors	CI

Quest PharmaTech Inc. Reports Earnings Results for the Full Year Ended January 31, 2024

May 29, 2024 at 04:08 pm EDT

Quest PharmaTech Inc. reported earnings results for the full year ended January 31, 2024. For the full year, the company reported net loss was CAD 3.02 million compared to CAD 64.89 million a year ago. Basic loss per share from continuing operations was CAD 0.018 compared to CAD 0.384 a year ago.

Latest news about Quest PharmaTech Inc.

Quest PharmaTech Inc. Reports Earnings Results for the First Quarter Ended April 30, 2024	Jun. 28	CI
Quest Pharmatech Inc. Announces the Appointment of Bradley J. Glass to the Board of Directors	May. 30	CI
Quest PharmaTech Inc. Reports Earnings Results for the Full Year Ended January 31, 2024	May. 29	CI
Quest PharmaTech Brief: Says Quest has a 42.5% ownership interest in OncoQuest; Adds dividend income will be used by Quest for general corporate purposes	Jan. 30	MT
Quest PharmaTech Brief: Received a cash dividend payment from OncoQuest Inc. of approximately C$685,000	Jan. 30	MT
Quest PharmaTech Inc. Says Oregovomab Phase III Clinical Study Fails Futility Analysis	Jan. 24	MT
Quest PharmaTech Inc. Receives Recommendations from the Data Safety Monitoring Board to Discontinue Oregovomab Phase III Clinical Study	Jan. 23	CI
Quest PharmaTech Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended October 31, 2023	Dec. 13	CI
Quest PharmaTech Inc. Reports Earnings Results for the Second Quarter and Six Months Ended July 31, 2023	23-09-21	CI
Quest PharmaTech Provided Product Development Update	23-07-10	MT
Quest PharmaTech Inc. Provides Product Development Update	23-07-10	CI
Quest PharmaTech Inc. Reports Earnings Results for the First Quarter Ended April 30, 2023	23-06-29	CI
Quest PharmaTech Inc. Reports Earnings Results for the Full Year Ended January 31, 2023	23-05-31	CI
Quest PharmaTech Inc. Auditor Raises 'Going Concern' Doubt	23-05-30	CI
Quest PharmaTech Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended October 31, 2022	22-12-18	CI
Quest PharmaTech Details Bioceltran Interest Sale, Return of Photodynamic Therapy Technology License	22-09-28	MT
Sang Ho Jang acquired unknown minority stake in Bioceltran Co., Ltd from Quest PharmaTech Inc. for CAD 0.3 million.	22-09-27	CI
Quest PharmaTech Inc. Reports Earnings Results for the Second Quarter and Six Months Ended July 31, 2022	22-09-26	CI
Quest PharmaTech Inc. Reports Earnings Results for the First Quarter Ended April 30, 2022	22-06-27	CI
Quest PharmaTech Inc. Reports Earnings Results for the Full Year Ended January 31, 2022	22-05-26	CI
Quest PharmaTech Inc. Auditor Raises 'Going Concern' Doubt	22-05-25	CI
Quest PharmaTech Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended October 31, 2021	21-12-23	CI
Quest Pharmatech Inc. Reports Earnings Results for the Second Quarter Ended July 31, 2021	21-09-23	CI
Quest PharmaTech Inc. Approves Appointment of J. Mark Lievonen and Jeffrey Shon as Board of Directors	21-07-07	CI
Quest Pharmatech Inc. Reports Earnings Results for the First Quarter Ended April 30, 2021	21-06-22	CI

Chart Quest PharmaTech Inc.

Duration

Period

More charts

Company Profile

Quest PharmaTech Inc. is a Canadian biopharmaceutical company. The Company is developing products to improve the quality of life. It is developing the proprietary, MAb-AR9.6, targeting MUC16 as a diagnostic agent for cancer. MAb-AR9.6 is licensed from the University of Nebraska Medical Centre and is in late preclinical stage development. The Company has a 42.5% ownership interest in OncoQuest Inc., which is a biotechnology company developing combinatorial immunotherapy products for the treatment of cancer. OncoQuest Inc.âs technology platform includes a panel of tumor antigen specific monoclonal antibodies of the immunoglobulin G (IgG) and E (IgE) class targeting CA125, MUC1, PSA, Her2/neu, CA 19.9 and TAG72; and the application of combinatorial immunotherapy to enhance tumor specific immunity and clinical outcome. The Company also has a 23% ownership interest in OncoVent, which is developing antibody-based immunotherapeutic products for cancer in the Greater China territory.

Sector

Biotechnology & Medical Research

Calendar

2024-09-18 - Q2 2025 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
QUEST PHARMATECH INC.	-45.45%	3.73M
MODERNA, INC.	+22.10%	46.55B
LONZA GROUP AG	+46.45%	41.84B
IQVIA HOLDINGS INC.	-3.12%	40.84B
ALNYLAM PHARMACEUTICALS, INC.	+36.10%	32.95B
CELLTRION, INC.	-6.30%	28.27B
ICON PUBLIC LIMITED COMPANY	+18.71%	27.78B
UNITED THERAPEUTICS CORPORATION	+46.15%	14.26B
MEDPACE HOLDINGS, INC.	+44.52%	13.69B
BIO-TECHNE CORPORATION	+0.19%	12.18B

Other Biotechnology & Medical Research